Free Trial

Inogen (INGN) Stock Price, News & Analysis

-0.15 (-1.71%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
185,830 shs
Average Volume
512,845 shs
Market Capitalization
$203.02 million
P/E Ratio
Dividend Yield
Price Target

Inogen MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
18.7% Downside
$7.00 Price Target
Short Interest
8.40% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of Inogen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$85,600 Sold Last Quarter
Proj. Earnings Growth
From ($2.43) to ($1.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

478th out of 921 stocks

Surgical Appliances & Supplies Industry

11th out of 18 stocks

INGN stock logo

About Inogen Stock (NASDAQ:INGN)

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

INGN Stock Price History

INGN Stock News Headlines

Inogen (NASDAQ:INGN) PT Raised to $7.00 at Stifel Nicolaus
Stifel Nicolaus Reaffirms Their Hold Rating on Inogen (INGN)
Q1 2024 Inogen Inc Earnings Call
Inogen: Q1 Earnings Snapshot
INGN Apr 2024 10.000 call
INGN Apr 2024 5.000 put
INGN Apr 2024 15.000 call
INGN Apr 2024 12.500 call
INGN Apr 2024 7.500 put
See More Headlines
Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical appliances & supplies
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$315.66 million
Book Value
$8.79 per share


Free Float
Market Cap
$203.02 million

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin R. M. Smith (Age 53)
    President, CEO & Director
    Comp: $1.62M
  • Mr. Jason Somer (Age 56)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $401.03k
  • Dr. Stanislav Glezer M.D. (Age 51)
    MBA, Executive VP of R&D and Chief Medical Officer
    Comp: $575.36k
  • Mr. Michael J. Bourque (Age 61)
    Executive VP, CFO & Treasurer
  • Mr. Philip Corrin
    Senior Vice President of Operations & Supply Chain
  • Ms. Jennifer Yi Boyer
    Executive VP & Chief Human Resources Officer
  • Mr. Vijay Paliwal
    Senior Vice President of Enterprise Enablement
  • Mr. Grgoire Ramade (Age 54)
    Executive VP & Chief Commercial Officer

INGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Inogen stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings
or view top-rated stocks.

What is Inogen's stock price target for 2024?

4 analysts have issued twelve-month price objectives for Inogen's shares. Their INGN share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests that the stock has a possible downside of 18.7%.
View analysts price targets for INGN
or view top-rated stocks among Wall Street analysts.

How have INGN shares performed in 2024?

Inogen's stock was trading at $5.49 at the beginning of the year. Since then, INGN stock has increased by 56.8% and is now trading at $8.61.
View the best growth stocks for 2024 here

When is Inogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our INGN earnings forecast

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings results on Tuesday, May, 7th. The medical technology company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.14. The medical technology company had revenue of $78.03 million for the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative trailing twelve-month return on equity of 42.87% and a negative net margin of 30.07%. The business's revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) EPS.

What ETF holds Inogen's stock?

Invesco Nasdaq Future Gen 200 ETF holds 6,173 shares of INGN stock, representing 0.70% of its portfolio.

What guidance has Inogen issued on next quarter's earnings?

Inogen updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $84.2 million.

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (8.38%), Vanguard Group Inc. (6.05%), Acadian Asset Management LLC (1.76%), Jacobs Levy Equity Management Inc. (1.58%), Tocqueville Asset Management L.P. (0.40%) and BNP Paribas Financial Markets (0.19%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Holdings A/S Novo, Jason Somer, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INGN) was last updated on 5/21/2024 by Staff

From Our Partners